<DOC>
	<DOCNO>NCT01265017</DOCNO>
	<brief_summary>This randomize , double-masked , placebo-controlled , single-center study evaluate stimulate C-peptide secretion exogenous administration mild immunosuppression growth-promoting factor woman preexist T1DM decline insulin requirement detectable C-peptide previous pregnancy . Fifteen subject enrol randomly assign 2:1 ratio either active treatment placebo parallel group design . Participation individual subject consist initial Screening Visit , 2-week baseline period , Baseline Visit , visit week 2 4 treatment period , visit end treatment period ( week 6 ) , follow-up visit 2 week study treatment discontinuation . Subjects receive either active treatment match placebo estradiol 1 mg every 8 hour ; medroxyprogesterone 2.5 mg every 24 hour ; hydrocortisone 2.5 mg every morning , 1.25 mg every afternoon , 1.25 mg bedtime night ; growth hormone 2 mg day ) .</brief_summary>
	<brief_title>Role Pregnancy Related Hormones Lowering Insulin Requirement Pregnant Women With Type 1 Diabetes</brief_title>
	<detailed_description>The primary objective study determine whether woman preexist T1DM show decline insulin requirement , define decrease insulin requirement 25 % , decrease deem clinically significant investigator , medically determine reason , detectable C-peptide previous pregnancy show change stimulate C peptide response pregnant treat exogenous pregnancy-related hormone growth factor ( Estradiol , medroxyprogesterone , hydrocortisone , GH ) 6 week . The secondary objective study follow : - Determine whether study treatment lead change T1DM autoantibody Baseline Week 6 - Determine percentage subject experience clinically significant decline total daily insulin requirement Week 6 , define 25 % decrease Baseline - Descriptively evaluate association serum level growth hormone , cortisol , prolactin change C-peptide level - Evaluate safety administration study treatment compare placebo , measure blood pressure , pulse , weight change , blood glucose , adverse event ( AEs )</detailed_description>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Medroxyprogesterone</mesh_term>
	<mesh_term>Medroxyprogesterone Acetate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<criteria>Female age 18 year old T1DM document history least one following : Decrease insulin requirement medically determine reason Detectable Cpeptide Free systemic corticosteroid use within 3 month study entry . Stable weight ( Â±10 % ) Stable diet exercise Stable insulin requirement ( &lt; 20 % variability insulin 2 week prior screen ) Normal renal function measure estimate glomerular filtration rate ( simple MDRD ) Negative pregnancy test planning become pregnant study period . The subject must willing use effective nonhormonal method birth control study . Able provide write informed consent . Diagnosis type 2 diabetes . Abnormal thyroid function ( thyroidstimulating hormone [ TSH ] free thyroxine [ FT4 ] test result ) define TSH &lt; 0.4mIU/L TSH &gt; 4.5mIU/L Free T4 &lt; 0.6ng/dL Free T4 &gt; 1.6ng/dL . Abnormal renal function , define serum creatinine great 1.2 mg/dL Any medical condition , opinion investigator , yield subject suitable study participation , include history stroke , cancer , hypercoagulable problem , risk deep vein thrombosis , unstable hormonal condition , Addison 's disease growth hormone deficiency . Currently treat systemic steroid , hydrocortisone , growth hormone , immunomodulatory medication Currently lactate . Pregnant within last 9 month . Menopausal Taking hormonal therapy Known hypersensitivity medication use study component formulation . Known eat disorder History phlebitis</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>type 1 diabetes</keyword>
	<keyword>pregnancy</keyword>
	<keyword>insulin requirement</keyword>
</DOC>